Monopar Therapeutics Inc (MNPR)


Stock Price Forecast

Feb. 16, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Monopar Therapeutics Inc chart...

About the Company

Monopar Therapeutics is a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. Monopar's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients; camsirubicin for the treatment of advanced soft tissue sarcoma; and a late-stagepreclinical antibody, MNPR-101, for advanced cancers and severe COVID-19.

Employees

10

Exchange

NASDAQ

Website

www.monopartx.com

$M

Total Revenue

10

Employees

$30M

Market Capitalization

-3.00

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $MNPR News

Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments

23h ago, source:

WILMETTE, Ill., March 28, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on ...

Monopar Therapeutics (MNPR) Earnings Dates & Reports

1d ago, source: Investing

View upcoming earnings forecasts and in-depth analysis of company forecasts.

Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program

24d ago, source: Business Insider

WILMETTE, Ill., March 05, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer ...

Monopar shares rise on positive tumor imaging data

23d ago, source: Investing

WILMETTE, Ill. - Monopar Therapeutics Inc . (NASDAQ:MNPR), a biopharmaceutical company engaged in the development of cancer treatments, today announced new preclinical imaging data showing ...

Monopar Therapeutics Inc.: Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical Trial

1mon ago, source: Finanznachrichten

WILMETTE, Ill., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer ...

Monopar Therapeutics Inc.: Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments

19h ago, source:

Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients ...

Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program

23d ago, source: Stockhouse

WILMETTE, Ill., March 05, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, ...

Monopar Therapeutics Inc (MNPR)

28d ago, source: Investing

Monopar Therapeutics Inc . (Nasdaq: NASDAQ:MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced... Monopar Therapeutics ...

Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program

24d ago, source: ADVFN

Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced positive preclinical imaging ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...